IL3RA/CD123
Alpha Lifetech can provide IL3RA/CD123 corresponding products, help each customer's research and development.
01
Introduction To IL3RA/CD123
Drug targets a biomolecule that can directly bind to drugs and then react. Generally, the target refers to a protein related to the cause of disease. The focus of the target began with focusing on tumors and then began to spread to various fields. Introduction to IL3RA/CD123 protein is a common target in medicine.
CD123 is the α -chain of the interleukin 3 receptor (IL-3R), and IL-3R is a member of the β co-receptor family. CD123 contains three extracellular domains (287 amino acids), a transmembrane domain (30 amino acids), and a short intracellular domain (53 amino acids). CD123 is usually expressed on hematopoietic stem cells, and it is also overexpressed on tumor cells such as acute myeloid leukemia, acute lymphoblastic leukemia, and hairy cell leukemia, promoting excessive proliferation of tumor cells. Therefore, CD123 becomes an effective target for the treatment of AML.
Function of Target IL3RA/CD123
Interleukin 3 (IL-3) promotes the development of hematopoietic cells through the activation of the IL-3 receptor (IL-3R) complex. CD123 is highly expressed on the surface of various cells (such as leukemic stem cells and LSCs) and is associated with the development and development of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The expression of CD123 is upregulated in leukemic stem cells and leukemic cells, making it a useful diagnostic and therapeutic biomarker in hematological malignancies. IL-3R is one of the target molecules involved in stimulating the proliferation of AMLs. The overexpression of the IL-3R α chain may be the mechanism leading to the development of a highly malignant leukemia phenotype. The involvement of IL-3 receptor beta common (IL-3R beta c) contributes to IL-3-and VE GF-induced Rac 1 activation, cell migration, and the formation of tubular structures in vitro.
Gene Pathway of Target IL3RA/CD123
IL-3 Ra recruits the IL-3R β chain to form a heterodimer and activates signals downstream of the intracellular receptor cascade, which then activates JAK / STAT, Ras-MAPK, and PI3-K pathways to mediate cell proliferation and survival. Upon fibronectin adhesion, Janus kinase 2 (JAK 2) is recruited to the β 1 integrin-IL-3R complex and triggers co-phosphorylation of IL-3R β, thus forming a docking site for activated STAT5A and affecting cell cycle progression in adherent cells. RNFT 2 (ring finger transmembrane domain-containing protein 2, also TMEM118), a previously uncharacterized RING finger ubiquitin E3 ligase, negatively regulates IL-3-dependent cellular responses through IL-3R α ubiquitination and degradation in the proteasome.
Fig 1: CD123 Gene Pathway. (Reference source: Espinoza-Gutarra MR, Green SD, Zeidner JF, Konig H. CD123-targeted therapy in acute myeloid leukemia. Expert Rev Hematol. 2021 Jun;14(6):561-576.)
Alpha Lifetech Can Provide
Currently, various immune drugs targeting IL3RA/CD123 targets are in the updating iteration, and taking the disease alone or in combination with other products has become a new approach with remarkable achievements. The IL3RA/CD123 targets have shown important research value and application prospects in both biology and drug research and development. With further research and detection technology advances, IL3RA/CD123 target products are also essential in medical research. Alpha Lifetech can provide IL3RA/CD123 corresponding products and help each customer's research and development. Alpha Lifetech provides end-to-end biotechnology development solutions, from upstream cell culture optimization to downstream purification scale. Our process is validated through analytical techniques such as HPLC, SDS-PAGE, and mass spectrometry to ensure product consistency and regulatory compliance. By combining cutting-edge biotechnology expertise with flexible service models, we help clients accelerate project research progress and ensure smooth experimentation.
| Catalog Number | Product Name | Product Sizes |
|---|---|---|
| ADT1698 | 1mg,5mg | |
| ADT1251 | ADT1251-Flotetuzumab Biosimilar-Anti IL3RA/CD123/CD3E mAb- Research Grade | 1mg,5mg |
| ADT1621 | ADT1621-Talacotuzumab Biosimilar-Anti IL3RA/CD123 mAb- Research Grade | 1mg,5mg |
| ADT1445 | ADT1445-Nofetumomab Biosimilar-Anti IL3RA/CD123 mAb- Research Grade | 1mg,5mg |
Reference
[1] Shi M, Su RJ, Parmar KP, Chaudhry R, Sun K, Rao J, Chen M. CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia. Cardiovasc Hematol Disord Drug Targets. 2019;19(3):195-204.
[2] DiPippo AJ, Wilson NR, Pemmaraju N. Targeting CD123 in BPDCN: an emerging field. Expert Rev Hematol. 2021 Nov;14(11):993-1004.
[3] Patnaik MM, Mughal TI, Brooks C, Lindsay R, Pemmaraju N. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leuk Lymphoma. 2021 Nov;62(11):2568-2586.
Video Resources
If you have any questions, please feel free to contact us at any time.
Leave Your Message
2018-07-16
0102